search
Back to results

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Primary Purpose

HIV Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ritonavir
Lamivudine
Zidovudine
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Zidovudine, HIV Protease Inhibitors, Ritonavir, Lamivudine

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression. Antibiotics other than metronidazole. PCP prophylaxis. Regularly prescribed medications such as antipyretics, analgesics, allergy medicine, and oral contraceptives. Vitamins and herbal therapies. Concurrent Treatment: Allowed: Acupuncture. Visualization techniques. Patients must have: Documented HIV infection. CD4 count 100-300 cells/mm3. At least 3 consecutive months of prior AZT at a dosage of 500-600 mg bid, but with 5 weeks of antiretroviral washout prior to study entry. Consent of parent or guardian if less than 18 years old. Prior Medication: Required: Prior AZT at 500-600 mg bid at any time. PCP prophylaxis during antiretroviral washout. Allowed: Prior ddI and/or ddC. Prior recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Chronic pancreatitis. Psychological conditions that would affect compliance. Intolerance to 500-600 mg/day AZT. Concurrent participation on another antiretroviral research treatment study (study treatment for opportunistic infection or complications of HIV is allowed). Considered likely to be noncompliant on study. Concurrent Medication: Excluded: Immunomodulators such as systemic corticosteroids, thalidomide, or cytokines. Rifabutin. Disulfiram (Antabuse) or other medications with similar effects, including metronidazole. Other drugs contraindicated with ritonavir. [AS PER AMENDMENT 8/27/96: Immunization must be avoided during the antiretroviral washout period.] Patients with the following prior conditions are excluded: Active opportunistic infection or febrile illness with temperature >= 38.5 C within 3 days prior to study entry. History of acute pancreatitis within the past 2 years. Prior Medication: Excluded: Prior 3TC or a protease inhibitor. Experimental drugs except those for HIV-related conditions, within the past 30 days. [AS PER AMENDMENT 8/27/96: Immunization must be avoided prior to the antiretroviral washout period.] Active substance abuse.

Sites / Locations

  • University of Colorado Hospital CRS
  • Rush Univ. Med. Ctr. ACTG CRS
  • Case CRS

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
October 28, 2021
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT00001075
Brief Title
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
Official Title
A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

4. Oversight

5. Study Description

Brief Summary
To determine whether administration of a highly active antiretroviral treatment regimen consisting of ritonavir (ABT-538), zidovudine (AZT), and lamivudine (3TC) is associated with the restoration of delayed type hypersensitivity and lymphocyte proliferative responses in patients with moderately advanced HIV-1 infection. To better characterize in these patients the phenotype of the expanded lymphocyte subpopulations, as well as the genotype, phenotype, and cellular origin of viruses that persist after initiation of therapy, and the genotype and phenotype of drug-resistant isolates that emerge during therapy. Although plasma viral load drops dramatically after initiation of powerful antiretrovirals, it does not drop to zero. It appears that a new steady state is reached, suggesting that a reservoir may exist of virus-producing cells, possibly cells of monocyte/macrophage lineage, that continue to produce a low level of virus despite antiretroviral treatment.
Detailed Description
Although plasma viral load drops dramatically after initiation of powerful antiretrovirals, it does not drop to zero. It appears that a new steady state is reached, suggesting that a reservoir may exist of virus-producing cells, possibly cells of monocyte/macrophage lineage, that continue to produce a low level of virus despite antiretroviral treatment. Patients undergo 5 weeks of antiretroviral washout before initiating therapy with ritonavir alone for 9 days, followed by combination therapy with ritonavir, zidovudine, and lamivudine from day 10 through week 48. [AS PER AMENDMENT 1/31/97: The availability of the current, open-label study treatment has been extended to allow patients who have completed 48 weeks of therapy to continue protocol therapy until the last enrolled patient completes 48 weeks of study treatment.]

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
Drug Therapy, Combination, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Antiviral Agents, Zidovudine, HIV Protease Inhibitors, Ritonavir, Lamivudine

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Enrollment
55 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Ritonavir
Intervention Type
Drug
Intervention Name(s)
Lamivudine
Intervention Type
Drug
Intervention Name(s)
Zidovudine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression. Antibiotics other than metronidazole. PCP prophylaxis. Regularly prescribed medications such as antipyretics, analgesics, allergy medicine, and oral contraceptives. Vitamins and herbal therapies. Concurrent Treatment: Allowed: Acupuncture. Visualization techniques. Patients must have: Documented HIV infection. CD4 count 100-300 cells/mm3. At least 3 consecutive months of prior AZT at a dosage of 500-600 mg bid, but with 5 weeks of antiretroviral washout prior to study entry. Consent of parent or guardian if less than 18 years old. Prior Medication: Required: Prior AZT at 500-600 mg bid at any time. PCP prophylaxis during antiretroviral washout. Allowed: Prior ddI and/or ddC. Prior recombinant erythropoietin and/or G-CSF for AZT-related bone marrow suppression. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Chronic pancreatitis. Psychological conditions that would affect compliance. Intolerance to 500-600 mg/day AZT. Concurrent participation on another antiretroviral research treatment study (study treatment for opportunistic infection or complications of HIV is allowed). Considered likely to be noncompliant on study. Concurrent Medication: Excluded: Immunomodulators such as systemic corticosteroids, thalidomide, or cytokines. Rifabutin. Disulfiram (Antabuse) or other medications with similar effects, including metronidazole. Other drugs contraindicated with ritonavir. [AS PER AMENDMENT 8/27/96: Immunization must be avoided during the antiretroviral washout period.] Patients with the following prior conditions are excluded: Active opportunistic infection or febrile illness with temperature >= 38.5 C within 3 days prior to study entry. History of acute pancreatitis within the past 2 years. Prior Medication: Excluded: Prior 3TC or a protease inhibitor. Experimental drugs except those for HIV-related conditions, within the past 30 days. [AS PER AMENDMENT 8/27/96: Immunization must be avoided prior to the antiretroviral washout period.] Active substance abuse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lederman M
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Kessler H
Official's Role
Study Chair
Facility Information:
Facility Name
University of Colorado Hospital CRS
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Rush Univ. Med. Ctr. ACTG CRS
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Case CRS
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
10608789
Citation
Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, Sevin AD, Fox L, Chiozzi MH, Leonard JM, Rousseau F, D'Arc Roe J, Martinez A, Kessler H, Landay A. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan;181(1):358-63. doi: 10.1086/315171.
Results Reference
background
PubMed Identifier
9652425
Citation
Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, Kotzin BL, Fox L, Chiozzi MH, Leonard JM, Rousseau F, Wade M, Roe JD, Martinez A, Kessler H. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul;178(1):70-9. doi: 10.1086/515591.
Results Reference
background
PubMed Identifier
10413649
Citation
Kaushal S, Landay AL, Lederman MM, Connick E, Spritzler J, Kuritzkes DR, Kessler H, Levine BL, St Louis DC, June CH. Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol. 1999 Jul;92(1):14-24. doi: 10.1006/clim.1999.4726.
Results Reference
background
PubMed Identifier
10669331
Citation
Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244.
Results Reference
background
PubMed Identifier
11364173
Citation
Doepel L, Folkers G. NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases. NIAID AIDS Agenda. 1997 Mar:4, 11.
Results Reference
background
PubMed Identifier
10202843
Citation
Shapiro HM, Lederman M, Connick E, Kessler H, Kuritzkes DR, Landay AL. Small differences in CD4+ T-cell production may go unnoticed. AIDS. 1999 Feb 4;13(2):290-1. doi: 10.1097/00002030-199902040-00025. No abstract available.
Results Reference
background
PubMed Identifier
11361794
Citation
ACTG 315 drug cocktail restores immune function. AIDS Patient Care STDS. 1997 Jun;11(3):193. doi: 10.1089/apc.1997.11.193. No abstract available.
Results Reference
background
PubMed Identifier
11559422
Citation
Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM; ACTG 315 Team. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 1;17(13):1231-40. doi: 10.1089/088922201750461285.
Results Reference
background
Citation
Lederman M, Connick E, Landay A, Kessler H, Kuritzkes D, St Clair M, Fox L, Heath-Chiozzi M, Rousseau F, Spritzler J. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir) preliminary results of ACTG 315. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:208 (abstract no LB13)
Results Reference
background
PubMed Identifier
10068574
Citation
Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard JM, Lederman MM. Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr;179(4):799-807. doi: 10.1086/314670.
Results Reference
background
PubMed Identifier
17392561
Citation
Gillespie EA, Gillespie BW, Stevens MJ. Painful diabetic neuropathy: impact of an alternative approach. Diabetes Care. 2007 Apr;30(4):999-1001. doi: 10.2337/dc06-1475. No abstract available.
Results Reference
derived

Learn more about this trial

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

We'll reach out to this number within 24 hrs